News

Dana-Farber/Boston Children's again named a top pediatric cancer program

Dana-Farber/Boston Children's has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking's inception, earning more #1 rankings than any other program.

A. Thomas Look, MD, awarded 2021 Society of Memorial Sloan Kettering Prize recipient for contributions in pediatric oncology

The global prize is awarded annually to a researcher, physician, or team leader who has made a positive and lasting impact in the fight against pediatric cancer.

Alex’s Lemonade Stand Foundation awards $4.95 million to Dana-Farber/Boston Children’s researchers as part of its Crazy 8 Initiative to advance pediatric cancer research

The grant was given to Leonard Zon, MD, of Boston Children’s Hospital who will collaborate extensively with other scientists at Boston Children’s Hospital and Dana-Farber Cancer Institute, including Scott A. Armstrong, MD, PhD; Vijay G. Sankaran, MD, PhD; Fernando Camargo, PhD; and Serine Avagyan, MD, PhD.

Childhood cancer survivors, providers satisfied with video visits for long-term follow-up

A report by Dana-Farber/Boston Children's researchers on the study of video conferencing was published in the journal Pediatric Blood and Cancer.

Stuart Orkin receives $500,000 Gruber Genetics Prize for his groundbreaking research on the genetics of inherited blood disorders

His remarkable body of work has not only revolutionized our understanding of how these illnesses occur but has also led to promising new gene-based therapies for thalassemia and sickle cell disease, two inherited blood disorders that affect millions of people around the world.

Targeted therapy for children with leukemia can provide substantial benefit, study finds

Genomic testing of patient leukemia cells uncovers genetic alterations that can be targeted by drug therapies in many patients.

Stuart H. Orkin Receives the 2021 ISSCR Tobias Lecture Award

Established in 2015 and supported by the Tobias Foundation, the prize recognizes original and promising basic hematology research as well as direct translational or clinical research related to cell therapy in hematological disorders.

In landmark study, an arthritis drug appears to prevent deadly acute graft-versus-host disease after bone marrow transplant

Abatacept (Orencia) reduces rates of acute GVHD, boosts survival in Phase 2 multicenter trial.

Dana-Farber/Boston Children's Faculty Named 2021 Top Doctors

Boston magazine has named a number of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center faculty members to its annual "Top Doctors" guide.

Amazon surprises Dana-Farber/Boston Children’s with a $500,000 donation during Childhood Cancer Awareness Month

The gift will support pediatric research, holiday gifts, and virtual events for pediatric patients and their families as part of the company’s global Amazon Goes Gold campaign during Childhood Cancer Awareness Month.